Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$8.23
+11.5%
$8.70
$6.57
$105.00
$268.52M1.03118,290 shs124,711 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.98
+0.4%
$3.55
$2.57
$6.88
$24.59M0.642,828 shs1,379 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.91
+1.9%
$1.89
$1.35
$53.79
$23.30MN/A176,718 shs91,910 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.54
+3.6%
$0.48
$0.30
$4.28
$36.62M-0.052.74 million shs2.69 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+11.52%+11.82%-5.51%+822,999,900.00%+822,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.03%+3.52%+8.90%+18.66%-27.73%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+1.87%-3.05%-18.38%+17.90%-95.10%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+3.56%-0.28%+27.91%-47.72%-36.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
1.7902 of 5 stars
3.50.00.00.01.81.70.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.5448 of 5 stars
3.14.00.00.01.81.70.6
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.6965 of 5 stars
3.61.00.00.02.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
3.00
Buy$16.0094.41% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17537.00% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.13
Buy$7.171,230.86% Upside

Current Analyst Ratings Breakdown

Latest JBIO, RVPH, QTTB, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $3.00
8/18/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $2.00
8/14/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.00
7/14/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/16/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$14.00
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.18 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.22N/AN/A$13.32 per share0.30
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M20.09N/AN/A($1.00) per share-1.91
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A($0.01) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$69.63M-$30.330.00N/AN/A-51.96%-47.65%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.300.00N/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%N/A

Latest JBIO, RVPH, QTTB, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.15-$0.12+$0.03-$0.12N/AN/A
8/13/2025Q2 2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.43-$0.86-$0.43-$0.86N/AN/A
8/6/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14-$0.78+$0.36-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
10.31
10.31
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
5.06
5.06
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.90
0.54

Institutional Ownership

CompanyInstitutional Ownership
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
24.90%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2032.63 million24.50 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
568.00 million49.52 millionOptionable

Recent News About These Companies

What is Zacks Small Cap's Estimate for RVPH FY2025 Earnings?
Roth Capital Issues Negative Outlook for RVPH Earnings
RVPH: There May Be A Faster Way
Reviva Narrows Loss 23% in Fiscal Q2
Reviva Dives on Stock Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$8.23 +0.85 (+11.52%)
As of 08/22/2025 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.95 -0.01 (-0.23%)
As of 08/22/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.91 +0.04 (+1.87%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.89 -0.02 (-1.05%)
As of 08/22/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.54 +0.02 (+3.56%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.54 0.00 (-0.65%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.